Home › Compare › ZGBEF vs ABBV
ZGBEF yields 0.28% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, ZGBEF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ZGBEF + ABBV for your $10,000?
2G Energy AG, together with its subsidiaries, develops, manufactures, and installs combined heat and power (CHP) systems, and other systems for the recovery of electrical energy in Germany and internationally. It offers decentralized power and heat through gas motors driven by natural gas, biomethane, biogas, sewage gas, landfill gas, or hydrogen with an electrical output of 20 to 4,500 kW. The company's products include g-box, a natural gas CHP plant with the electrical output of 20 kW to 50 kW; aura, a CHP plant with the output range from 100 kW to 420 kW; patruus, a biogas and natural gas CHP plant with the output range from 50 kW to 263 kW; agenitor, a CHP plant with a capacity of 220 kW to 450 kW; and avus, a CHP plant with the electrical output range of 400 kW to 4.000 kW. It also engages in the rental and leasing of CHP plants. The company's products are used for various applications, such as biogas plants, office and administrative buildings, chemical and pharmaceutical industries, landfills, shopping centers, horticultural and agricultural holdings, hotels, industry and trade, sewage treatment plants, hospitals, food industry, public institutions, data processing centers, schools and universities, swimming pools, senior citizen centers, sports and leisure centers, heat grids, hydrogen, and residential buildings. The company was formerly known as 2G Bio-Energietechnik AG and changed its name to 2G Energy AG in 2011. 2G Energy AG was founded in 1995 and is headquartered in Heek, Germany.
Full ZGBEF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.